Adoption of teletherapy has seen remarkable growth across different age groups, with 54% of Americans having had at least one telehealth visit as of early 2024. The satisfaction rate for these services is impressively high, with 89% of users expressing contentment with their last appointment1. Younger adults (18-29) are leading the charge, with 66% having used telehealth services, while 36% of older adults have embraced these digital platforms. This generational divide in usage suggests that while teletherapy is gaining traction across all demographics, it's particularly appealing to younger generations who are more comfortable with digital technologies. The trend is further supported by the fact that over 116 million users globally are engaging in online doctor consultations in 2024.

TMS therapy has demonstrated remarkable success in treating depression, particularly for patients who haven't responded well to traditional treatments. Studies indicate that 50-60% of individuals undergoing TMS experience significant symptom improvement, with approximately one-third achieving full remission after completing their initial treatment course. This impressive effectiveness offers hope to those struggling with persistent depressive symptoms, providing a viable alternative when other methods have fallen short.

Esketamine has emerged as a groundbreaking therapy for treatment-resistant depression (TRD), offering rapid relief and new hope for patients who have not responded to conventional antidepressants. In a landmark 32-week randomized trial, esketamine nasal spray demonstrated superior efficacy compared to extended-release quetiapine when used as an augmentation to SSRIs or SNRIs. Key findings include: